FDA Continues to Get it Wrong with Pradaxa
By Ned McWilliams November 26th, 2012 9:00am Pradaxa, the popular and new blood-thinning medication meant to protect those with atrial fibrillation from stroke continues to generate safety concerns among doctors, patients and international regulators. Despite these growing concerns, the United States FDA has continued its defense of the drug and its decision to approve it – even going so far as to allow Pradaxa’s owner, German pharmaceutical giant Boehringer Ingelheim, to promote the drug in a manner that the FDA has internally stated is of questionable scientific integrity. Pradaxa was studied and is being marketed in comparison to Coumadin...
Read More